Patents by Inventor Kathryn Stolz

Kathryn Stolz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7465726
    Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    Type: Grant
    Filed: August 1, 2005
    Date of Patent: December 16, 2008
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Saleh Ahmed, Oscar Barba, Jason Bloxham, Graham Dawson, William Gattrell, John Kitchin, Neil Anthony Pegg, Imaad Saba, Shazia Sadiq, Colin Peter Sambrook Smith, Don Smyth, Amo G. Steinig, Robin Wilkes, Bijoy Panicker, Paula Tavares, Matthew Cox, An-Hu Li, Hanqing Dong, Lifu Ma, Kenneth (‘Ken’) Foreman, Qinghua (‘Felix’) Weng, Kathryn Stolz
  • Publication number: 20070129364
    Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least one of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Met, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    Type: Application
    Filed: December 5, 2006
    Publication date: June 7, 2007
    Inventors: Han-Qing Dong, Kenneth Foreman, An-Hu Li, Mark Mulvihill, Bijoy Panicker, Arno Steinig, Kathryn Stolz, Qinghua Weng, Meizhong Jin, Brian Volk, Jing Wang, Ti Wang, James Beard
  • Publication number: 20060211678
    Abstract: Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mek1, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2, IGF-1R, Ron, Ret, and KDR kinases in animals, including humans, for the treatment and/or prevention of various diseases and conditions such as cancer.
    Type: Application
    Filed: August 1, 2005
    Publication date: September 21, 2006
    Inventors: Saleh Ahmed, Oscar Barba, Jason Bloxham, Graham Dawson, Wiliam Gattrell, John Kitchin, Neil Anthony Pegg, Imaad Saba, Shazia Sadiq, Colin Peter Sambrook Smith, Don Smyth, Amo Steing, Robin Wilkes, Bijoy Panicker, Paula Tavares, Matthew Cox, An-Hu Li, Hanqing Dong, Lifu Ma, Kenneth Foreman, Qinghua Weng, Kathryn Stolz